In fact, approximately 15–25% of all metastatic tumors were shown to have NRAS mutation (Boespflug et al., 2017), and the associations of NRAS with chemotherapy resistance were shown (Nguyen et al., 2020) in melanoma. Here, NRAS is linked to metastatic neoplasm.